A director at Glanbia bought 5,000 shares at 10.410EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
>GPN’s 2025 margin is expected in line with H2 2024 at 15% as whey prices are expected to continue rising until H1 2025 - GPN’s organic growth of -0.8%, in 9M as in Q3, reflected a volume effect of 3.2% which was partly offset by a price effect of -4%. Sales were almost flat in the Americas despite SlimFast having a negative impact (-33%). Excluding this effect, growth would have reached 5%. GPN is growing internationally (+4.7%) thanks to healthy momentum in its ON ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.